Novo Nordisk licenses global rights to potential new haemostasis therapy

Novo NordiskNovo Nordisk has entered a global licence agreement with French biotechnology company C2X Pharma and the French national institute for health and medical research (Inserm) for thrombin-activable factor X. The protein, which is in early preclinical development, is a novel type of bypassing agent, capable of propagating blood clotting independently of factors VIII and IX. Novo Nordisk intends to explore the protein's potential for becoming a new treatment option for haemophilia and other critical bleeding conditions.

The agreement supports Novo Nordisk's ambition to expand its portfolio of projects within haemophilia and haemostasis through partnerships with biotech companies and research institutions around the world.

Thrombin-activable factor X was discovered by Professor Martine Aiach, Doctor Bernard Le Bonniec, Doctor Pierre-Emmanuel Marque and their team at Unit Inserm 428 (Pharmaceutical and Biological Sciences Faculty at René Descartes University) and further developed to its current stage by C2X Pharma.

About Novo Nordisk
Novo Nordisk is a healthcare company and a world leader in diabetes care. The company has the broadest diabetes product portfolio in the industry, including the most advanced products within the area of insulin delivery systems. In addition, Novo Nordisk has a leading position within areas such as haemostasis management, growth hormone therapy and hormone replacement therapy. Novo Nordisk manufactures and markets pharmaceutical products and services that make a significant difference to patients, the medical profession and society. With headquarters in Denmark, Novo Nordisk employs approximately 25,800 employees in 79 countries, and markets its products in 179 countries. Novo Nordisk's B shares are listed on the stock exchanges in Copenhagen and London. Its ADRs are listed on the New York Stock Exchange under the symbol 'NVO'. For more information, visit www.novonordisk.com.

Most Popular Now

73,000 Scientists collaborate over new COVID-19 Da…

More than 73,000 users collaborate on new online platform set up by the European Open Science Cloud Initiative, where scientists share COVID-19 data and accelerate our un...

Antiviral used to treat cat coronavirus also works…

Researchers at the University of Alberta are preparing to launch clinical trials of a drug used to cure a deadly disease caused by a coronavirus in cats that they expect ...

Search for COVID-19 drugs boosted by SARS discover…

An extensive search and testing of current drugs and drug-like compounds has revealed compounds previously developed to fight SARS might also work against COVID-19. Us...

Pfizer and BioNTech share positive early data on l…

Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) shared additional Phase 1 safety and immunogenicity data from their ongoing U.S. study of the BNT162 mRNA-based vac...

Phase I clinical trial initiated for monoclonal an…

The first participants have been dosed in a Phase I trial of AZD7442, a combination of two monoclonal antibodies (mAbs) in development for the prevention and treatment of...

Europe's largest initiative launches to accelerate…

CARE (Corona Accelerated R&D in Europe) a new consortium supported by the Innovative Medicines Initiative (IMI) public-private partnership announced its launch to acceler...

Vitamin D deficiency may raise risk of getting COV…

In a retrospective study of patients tested for COVID-19, researchers at the University of Chicago Medicine found an association between vitamin D deficiency and the like...

Blocking cellular communication stops SARS-CoV-2

In the transmission of signals within the cell which, for example, stimulate cell growth or trigger metabolic processes, phosphate groups play an important biochemical ro...

Improving FDA's COVID-19 vaccine authorization and…

On March 28, the Food and Drug Administration (FDA) exercised its Emergency Use Authorization (EUA) authority to allow the use of hydroxychloroquine for the treatment of ...

Steroid found to improve survival of critically il…

A new international study published today has shown that treating critically ill patients with COVID-19 with the steroid hydrocortisone improves their chances of recovery...

Bayer and Informed Data Systems Inc. (One Drop) jo…

Bayer and Informed Data Systems Inc. (One Drop), a US-based digital health company, today announced that they have entered into an agreement to jointly develop digital he...

Abbott's fast, $5, 15-minute, easy-to-use COVID-19…

Abbott (NYSE: ABT) announced that the U.S. Food and Drug Administration (FDA) has issued Emergency Use Authorization (EUA) for its BinaxNOW™ COVID-19 Ag Card rapid test f...